Hundreds of newborns are now being tested for over 200 rare genetic conditions as part of a groundbreaking study launched at Leeds Teaching Hospitals NHS Trust (LTHT).
This innovative research seeks to detect conditions like Metachromatic Leukodystrophy (MLD) in babies at an earlier stage, potentially benefiting hundreds through quicker diagnoses and treatments that could slow disease progression and enhance or prolong lives.
Led by Genomics England in collaboration with NHS England, the Generation Study offers whole genome sequencing for newborns using blood samples typically collected from the umbilical cord shortly after birth.
The sequencing enables the early identification of treatable, rare conditions before symptoms arise later in childhood, allowing families to access timely NHS support, monitoring, and treatment.
The Generation Study aims to detect over 200 conditions in asymptomatic babies, identifying potential health issues before symptoms develop. Early interventions could prevent long-term health complications, reduce hospitalisations, and help children lead healthier lives.
Expectant parents are introduced to the study during pregnancy. If interested, they engage in a detailed discussion with a research midwife to decide whether to participate.
After birth, parents confirm their consent with an NHS doctor or midwife, who collects a blood sample for genome sequencing.
NHS genomic scientists review the results, aiming to notify parents within 28 days if a condition is suspected or within a few months if no conditions are identified.
If genome sequencing reveals a treatable condition, families receive further NHS testing for confirmation, along with ongoing support and treatment.
In addition to helping families, the study will advance healthcare research by improving testing, discovering new treatments, and exploring the possibility of using a stored genome over an individual’s lifetime to predict, diagnose, and treat future illnesses.
